NDAORALTABLETPriority Review
Approved
Jan 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
13
Mechanism of Action
Janus Kinase Inhibitors
Pharmacologic Class:
Janus Kinase Inhibitor
Clinical Trials (5)
Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.
Started Jan 2026
150 enrolled
Atopic DermatitisAtopic Dermatitis, UnspecifiedDermatitis, Atopic
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
Started Dec 2025
500 enrolled
Atopic Dermatitis
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
Started Jul 2025
150 enrolled
Eczema
Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVID
Started Dec 2024
46 enrolled
Post-COVID ConditionFatigue Symptom
Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry)
Started Jul 2024
200 enrolled
Dermatitis, AtopicDermatitisEczema+3 more
Loss of Exclusivity
LOE Date
Jan 14, 2036
120 months away
Patent Expiry
Jan 14, 2036
Exclusivity Expiry
Jan 14, 2027